Bank of New York Mellon Corp decreased its holdings in Heron Therapeutics Inc (NASDAQ:HRTX) by 4.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 298,065 shares of the biotechnology company’s stock after selling 15,247 shares during the quarter. Bank of New York Mellon Corp’s holdings in Heron Therapeutics were worth $7,732,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of HRTX. Vanguard Group Inc grew its position in Heron Therapeutics by 36.7% during the 3rd quarter. Vanguard Group Inc now owns 6,193,249 shares of the biotechnology company’s stock worth $196,016,000 after purchasing an additional 1,661,318 shares in the last quarter. Vanguard Group Inc. grew its position in Heron Therapeutics by 36.7% during the 3rd quarter. Vanguard Group Inc. now owns 6,193,249 shares of the biotechnology company’s stock worth $196,016,000 after purchasing an additional 1,661,318 shares in the last quarter. Stelliam Investment Management LP grew its position in Heron Therapeutics by 250.8% during the 3rd quarter. Stelliam Investment Management LP now owns 517,500 shares of the biotechnology company’s stock worth $16,379,000 after purchasing an additional 370,000 shares in the last quarter. BlackRock Inc. grew its position in Heron Therapeutics by 5.2% during the 3rd quarter. BlackRock Inc. now owns 4,780,799 shares of the biotechnology company’s stock worth $151,313,000 after purchasing an additional 236,068 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in Heron Therapeutics by 458.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 206,802 shares of the biotechnology company’s stock worth $6,545,000 after purchasing an additional 169,738 shares in the last quarter.

Heron Therapeutics stock opened at $25.17 on Thursday. Heron Therapeutics Inc has a 12 month low of $21.25 and a 12 month high of $42.90. The firm has a market cap of $2.00 billion, a PE ratio of -10.32 and a beta of 1.56.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Friday, February 22nd. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.17). Heron Therapeutics had a negative net margin of 230.84% and a negative return on equity of 54.98%. The business had revenue of $28.84 million during the quarter, compared to analyst estimates of $28.05 million. As a group, sell-side analysts predict that Heron Therapeutics Inc will post -1.52 earnings per share for the current year.

Several equities analysts have recently commented on the stock. ValuEngine upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, January 8th. Cantor Fitzgerald cut shares of Heron Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, March 4th. BidaskClub upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 20th. Zacks Investment Research cut shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 9th. Finally, Northland Securities set a $55.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Tuesday, April 2nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $52.80.

COPYRIGHT VIOLATION WARNING: “Bank of New York Mellon Corp Sells 15,247 Shares of Heron Therapeutics Inc (HRTX)” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/bank-of-new-york-mellon-corp-sells-15247-shares-of-heron-therapeutics-inc-hrtx/2953954.html.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Further Reading: What is a trade deficit?

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.